Affiliation:
1. Federal State Autonomous Educational Institution of Higher Education «N.I. Pirogov Russian National Research Medical University» of the Ministry of Health of the Russian Federation
Abstract
NAFLD is a systemic metabolic disease that manifests itself in a variety of concomitant pathologies united by common pathophysiological mechanisms of development. NAFLD is the most common cause of chronic liver disease in the world, the prevalence of which in the general population is approximately 30% and occurs in all age categories and has no gender differences. Given the close relationship of NAFLD with metabolic syndrome, type 2 diabetes and obesity, as well as the huge contribution to the development of cardiorenal complications according to numerous studies, innovative hypoglycemic therapy in the treatment of patients with NAFLD and NASH is of particular interest. One of the most promising antidiabetic drugs, which, in addition to the hypoglycemic effect, have a dozen extraglycemic pleiotropic effects on cardiovascular, renal and hepatic function, are iNGLT type 2.